Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection....

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the...

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into...

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication...